Lexicon Pharmaceuticals, listed under NASDAQ:LXRX, has announced a quarterly loss of $0.03 per share. This result is an improvement compared to the Zacks Consensus Estimate, which anticipated a loss of $0.06 per share. In comparison, the company reported a loss of $0.04 per share in the same quarter last year. These figures have been adjusted to exclude non-recurring items, providing a clearer picture of the company’s ongoing performance.
This quarter’s results represent an earnings surprise of 50%. In the previous quarter, Lexicon was expected to post a loss of $0.06 per share, which is exactly what it delivered, resulting in no earnings surprise. Over the past four quarters, Lexicon has managed to exceed consensus earnings per share (EPS) estimates three times, indicating a trend of outperforming market expectations.
Lexicon operates within the Zacks Medical – Biomedical and Genetics industry, a sector known for its innovation and rapid development cycles. The company reported revenues of $11.25 million for the quarter ending September 2026, surpassing the Zacks Consensus Estimate by 3.21%. This result, however, is a decrease from the $14.18 million in revenue reported for the same period last year. Despite this year-over-year decline, Lexicon has exceeded consensus revenue estimates three times in the last four quarters, demonstrating its ability to perform above market predictions.
The immediate movement of Lexicon’s stock price following these results will largely depend on management’s commentary during the earnings call and the company’s future earnings expectations. Since the beginning of the year, Lexicon shares have appreciated by approximately 28.7%, outpacing the S&P 500’s gain of 12.3%. This performance highlights the company’s resilience and potential to deliver value to its shareholders.
Future Prospects for Lexicon
Despite Lexicon’s strong performance relative to the market this year, investors are keen to understand the stock’s future trajectory. A key factor in determining this is the company’s earnings outlook, which includes current consensus earnings expectations for upcoming quarters and any recent changes to these estimates. This outlook provides insight into how the company might perform in the near future.
Empirical research indicates a strong link between near-term stock price movements and trends in earnings estimate revisions. Investors can monitor these revisions themselves or use tools such as the Zacks Rank, which effectively utilizes earnings estimate revisions to predict stock performance. Prior to the earnings release, Lexicon’s estimate revisions trend was mixed, resulting in a Zacks Rank #3 (Hold). This suggests that the stock is expected to perform similarly to the market in the near term.
It will be important to observe how estimates for future quarters and the current fiscal year adjust in the coming days. The current consensus EPS estimate for the next quarter is -$0.04, with revenues projected at $10.73 million. For the current fiscal year, the EPS estimate is -$0.17 on $38 million in revenues. These estimates provide a benchmark for evaluating the company’s future financial performance.
Investors should also consider the impact of industry trends on Lexicon’s stock performance. The Zacks Industry Rank places the Medical – Biomedical and Genetics sector in the top 45% of over 250 industries. Historically, industries ranked in the top 50% outperform those in the bottom 50% by more than 2 to 1, suggesting that Lexicon is operating in a favorable industry environment.
Another company in the same industry, TG Therapeutics (NASDAQ:TGTX), is set to release its quarterly results for the period ending September 2026 on November 9. TG Therapeutics is expected to report quarterly earnings of $0.37 per share, representing a year-over-year decline of 84.8%. The consensus EPS estimate for TG Therapeutics has remained unchanged over the past 30 days. The company’s revenues are anticipated to reach $247.16 million, marking a 52.8% increase from the same quarter last year. This performance underscores the dynamic nature of the biopharmaceutical sector, where companies can experience significant fluctuations in earnings and revenue growth.
For those interested in more investment insights, Zacks Investment Research offers a list of the 7 Best Stocks for the Next 30 Days, providing additional opportunities for investors seeking to diversify their portfolios.
Footnotes:
- Lexicon reported a quarterly loss of $0.03 per share, better than the expected $0.06 loss. Source.
- Lexicon’s revenue for the quarter was $11.25 million, surpassing estimates by 3.21%. Source.
- TG Therapeutics is expected to report earnings of $0.37 per share, a significant year-over-year decline. Source.
Featured Image: Megapixl @ Terovesalainen
